Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1951 1
1956 1
1968 1
1969 1
1970 1
1971 1
1976 2
1977 1
1979 2
1980 5
1981 3
1982 2
1983 3
1984 2
1987 1
1989 2
1990 1
1993 2
1994 1
1995 2
1996 2
1997 1
1998 2
1999 1
2000 2
2001 5
2002 11
2003 10
2004 22
2005 43
2006 80
2007 144
2008 299
2009 120
2010 70
2011 68
2012 48
2013 48
2014 36
2015 23
2016 27
2017 21
2018 21
2019 20
2020 12
2021 12
2022 10
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 19118249

1,062 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Marcucci R, et al. Circulation. 2009 Jan 20;119(2):237-42. doi: 10.1161/CIRCULATIONAHA.108.812636. Epub 2008 Dec 31. Circulation. 2009. PMID: 19118249
High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Marcucci R, et al. Thromb Haemost. 2010 Aug;104(2):279-86. doi: 10.1160/TH10-01-0007. Epub 2010 May 27. Thromb Haemost. 2010. PMID: 20508896
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Patti G, et al. J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33. doi: 10.1016/j.jacc.2008.06.038. J Am Coll Cardiol. 2008. PMID: 18804738 Free article. Clinical Trial.
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Patti G, et al. Am J Cardiol. 2011 Apr 1;107(7):995-1000. doi: 10.1016/j.amjcard.2010.11.025. Epub 2011 Jan 20. Am J Cardiol. 2011. PMID: 21256470
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM; TIMI Study Group. Pride YB, et al. Am Heart J. 2009 Sep;158(3):e21-6. doi: 10.1016/j.ahj.2009.06.021. Am Heart J. 2009. PMID: 19699846 Clinical Trial.
1,062 results